Sab biotherapeutics announces executive leadership change

Sioux falls, s.d., feb. 02, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced samuel j. reich, currently the executive chairman of sab, will expand his role to include that of chief executive officer of sab, effective february 2, 2024.
SABS Ratings Summary
SABS Quant Ranking